Company intelligence
Windgap Medical, Inc.
Injecting simplicity into complex drug delivery
About Windgap Medical, Inc.
Windgap Medical offers autoinjector platforms for complex injectables, freeing patients, families and potential treatments from the limitations of current technology. Its first product is for the administration of adrenaline for anaphylaxis, with additional products under development.
Verified activity
Signals from Windgap Medical, Inc.
8 published signals
Presence & Recognition
Windgap Medical, Inc. built its platform for handheld devices delivering up to 10 mL to address the subcutaneous delivery volume mismatch.
Reported by Aaron Mann
Partnerships
Windgap Medical, Inc. partnered with Novartis and Alteogen for a $3.2 billion rights agreement to convert IV biologics into subcutaneous formulations using Hybrozyme technology.
Reported by Aaron Mann
Presence & Recognition
Windgap Medical, Inc. is attending the PODD event in Boston, MA.
Reported by Windgap Medical, Inc.
Presence & Recognition
Windgap Medical, Inc. is attending the PDA Universe of Pre-Filled Syringes & Injection Devices event in Palm Springs, CA.
Reported by Windgap Medical, Inc.
Presence & Recognition
Windgap Medical, Inc. is attending the CPHI Milan event in Milan, Italy.
Reported by Windgap Medical, Inc.
Presence & Recognition
Windgap Medical, Inc. team is attending the PDA - Parenteral Drug Association, CPHI Milan, and PODD conferences in October.
Reported by Brent Buchine
Research & Knowledge
Windgap Medical, Inc. published a framework from Eli Lilly and Company's device and delivery science group treating subcutaneous injection as one coupled system instead of four separate problems solved independently.
Reported by Aaron Mann
Research & Knowledge
Windgap Medical, Inc. highlights that the research from Peters, Nadkarni, and Bruker in June 2026 discusses next-gen platforms for highly concentrated biologics intended for subcutaneous delivery.
Reported by Aaron Mann